A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the korean cancer study group (LU17-19)

Post time 3 day(s) ago

journal：Lung Cancer

Authors：Yu Jung Kim; Soyeon Kim; Tae Min Kim; Koung Jin Suh; Miso Kim; Se Hyun Kim; Bhumsuk Keam; Dong-Wan Kim; Jong Seok Lee; Dae Seog Heo

Published date：2024-7-

DOI：10.1016/j.lungcan.2024.107870

PDF link：https://www.sciencedirect.com/sc ... 169500224004045/pdf

Article link：http://dx.doi.org/10.1016/j.lungcan.2024.107870

Article Source：Elsevier BV。

Remark：

Post time 3 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the korean cancer study group (LU17-19)

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the korean cancer study group (LU17-19) Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the korean cancer study group (LU17-19)